AstraZeneca, opens new tab said it will spend $2.5 billion on a research and development hub in Beijing, as the drugmaker scrambles to revive business in its second-biggest market after scandals including the arrest of its China president last year.
Chief Executive Pascal Soriot was in Beijing and met with the city's mayor to reveal the investment, along with two licensing deals with Chinese companies, and a joint venture with a third Chinese firm on vaccines, saying they all showed the company's commitment to the world's No. 2 economy.
"This $2.5 billion investment reflects our belief in the world-class life sciences ecosystem in Beijing, the extensive opportunities that exist for collaboration and access to talent, and our continued commitment to China," Soriot said in a statement.
The R&D centre "will partner with the cutting-edge biology and AI science in Beijing and be a critical part of our global efforts to bring innovative medicines to patients worldwide," Soriot said.
The centre in Beijing will be the company's second R&D site in China - a centre in Shanghai opened in 2024 - to match two such centres each that AstraZeneca has in the U.S. and Europe, respectively, a company spokesperson said.
The Chinese government has launched several investigations into AstraZeneca's executives and activities in the country, where the drugmaker has invested billions of dollars to build factories and license experimental drug candidates from Chinese biotech firms.
China accounted for about 12% of group revenue last year. The company, the UK's largest listed company worth 183 billion pounds ($236 billion) on the blue-chip FTSE 100 index, opens new tab, is the largest foreign drugmaker in China.
Soriot has often visited the country in recent years and praised the value of doing business there even when other multinationals complained of challenges or cited geopolitical tensions between China and Western countries as a risk for the pharma industry.
He is due to attend a flagship development conference in Beijing over the coming days where some are expected to meet Chinese President Xi Jinping.
The company put its former China head Leon Wang, who also led its international business as an executive vice president, on administrative leave following his detention by Chinese authorities in October, and overhauled its local management in China.
Soriot said at quarterly results last month that the company still does not know Wang's whereabouts. Its stock was hit hard by news of the probes in October 2024, but shares have since recovered as investors hope the impact could be minor.
A company spokesperson declined on Friday to comment on the status of the investigations.
The licensing agreements announced on Friday were with Chinese firms Harbour BioMed and Syneron Bio, for early-stage experimental medicines. The financial terms were not disclosed.
The deals were the latest of about a dozen AstraZeneca has signed with Chinese firms in the past several years - including on obesity drugs - worth a total of at least $9 billion, according to the company.
It is also launching a joint venture with another firm, BioKangtai, to develop, manufacture and commercialize vaccines for respiratory and other infectious diseases for patients in China and elsewhere. The site, in Beijing, will be the company's first vaccine manufacturing facility in the country.
The company on Friday also announced a partnership with state-run Beijing Cancer Hospital focused on data science and clinical development.
U.S. and Pakistani leaders forecast a Sunday signing of a long-elusive framework agreement to end fighting between the United States and Iran, as Reut...
Tajikistan has strengthened its position as one of Central Asia’s fastest-growing economies. According to the European Bank for Reconstruction and D...
The New York Knicks defeated the San Antonio Spurs 94-90 to close out the series 4-1 and claim their first NBA championship since 1973, sparking celeb...
In the runup to the G7 summit, hosted by France in Évian-les-Bains on Monday, 15 June, China has addressed global economic balances in a videoconfer...
Switzerland on Sunday rejected a referendum proposal to cap its population at 10 million, a projection showed, as voters prioritised economic stabilit...
A groundbreaking study presented at ASCO reveals that AstraZeneca’s experimental pill camizestrant, when used based on blood test results, can halve the risk of breast cancer progression or death—potentially reshaping treatment for patients with hormone receptor-positive, HER2-negative breast cancer
AstraZeneca is acquiring Belgium-based EsoBiotec for $1 billion to expand its cell therapy capabilities, with the deal set to close in the second quarter.
Pakistan has warned that any attempt by India to block or significantly reduce river flows under the Indus Waters Treaty could have “far-reaching consequences”, after India's water minister said New Delhi was working to ensure that “not a single drop” of water reaches Pakistan in the coming years.
SpaceX made a historic entrance into the Nasdaq on Friday, surging over 20% in its first day of trading and lifting its valuation to more than $2 trillion. Investors flocked to the world’s largest IPO, betting on Elon Musk’s sprawling empire spanning rockets, AI and beyond.
Armenia has every right to choose Europe. But Europe’s support for Armenia’s direction should not become automatic approval of its political process.
U.S. President Donald Trump has said a peace agreement with Iran is scheduled to be signed on Sunday in a post on social media, despite Tehran's Foreign Ministry spokesperson Esmaeil Baghaei saying no deal would be approved this weekend.
Japan’s birth rate and fertility levels have fallen to their lowest levels on record, highlighting the country’s worsening demographic crisis as fewer people marry and have children.
A U.S. doctor who contracted Ebola while on a humanitarian mission in the Democratic Republic of Congo has recovered and been discharged from a hospital in Germany, according to officials.
Protesters in Nanyuki blocked roads and burned tyres after residents challenged a U.S. plan to house Americans exposed to Ebola at a nearby military base.
Global health organisation CEPI will provide around $60 million to Moderna and two other partners to speed up the development of vaccines targeting the Ebola Bundibugyo strain, which is currently driving an outbreak in eastern Democratic Republic of Congo.
The head of the World Health Organization (WHO) has warned that the Ebola outbreak in the Democratic Republic of Congo may be significantly larger than official figures suggest, following a visit to the country where he briefed President Felix Tshisekedi on the ongoing response.
Four nurses have recovered and been discharged after receiving treatment for Ebola in the Democratic Republic of Congo, the World Health Organisation (WHO) said.
You can download the AnewZ application from Play Store and the App Store.
What is your opinion on this topic?
Leave the first comment